Zymergen
A biotechnology company that used synthetic biology, automation, genomics, and machine learning to develop bio-based chemicals and materials.
Last updated August 22, 2026
AI crawler reads
1requests
1companies- Anthropic1
- Profile
- 1
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
Since Oct 28, 2026 · from this site's server log
Overview
Zymergen was an American biotechnology company founded in 2013 and headquartered in Emeryville, California. It pursued a form of industrial biotechnology in which genetically modified microorganisms were designed and optimized to produce chemicals and material inputs through fermentation. The company combined genomic analysis, laboratory automation, machine learning, and biological engineering in an attempt to shorten the path from a promising biological pathway to a scalable commercial product. The founders—investment banker Joshua Hoffman, biophysicist Zach Serber, and biochemist Jed Dean—had previously worked together at Amyris. Zymergen presented its platform as an alternative to conventional petrochemical manufacturing, arguing that biological production could eventually create specialty chemicals and advanced materials with lower environmental impact, improved safety, and competitive economics. Its research interests included replacements for petroleum-derived products and biological routes to ingredients used in consumer goods, industrial applications, and pharmaceuticals. The company attracted substantial private financing during the 2010s, including investment from SoftBank’s Vision Fund, and reported relationships with government and corporate customers. In 2018 it acquired Radiant Genomics, another biotechnology company, to expand its capabilities. Despite its strong fundraising and high-profile synthetic-biology narrative, Zymergen experienced difficulty translating laboratory work into reliable manufacturing and recurring revenue. It also reduced its workforce during the COVID-19 period as it attempted to manage operating costs. Zymergen’s first publicly announced commercial product was Hyaline, introduced in December 2020. Hyaline was a bio-manufactured polyimide film made using biologically produced diamine monomers. The transparent and flexible film was promoted for possible use in electronics and optical applications, including flexible displays. The company went public in April 2021 in an initial public offering of approximately $500 million. Subsequent regulatory disclosures revealed that revenue remained limited, losses were substantial, and the company was having trouble producing Hyaline consistently. Customer and manufacturing difficulties undermined confidence in the commercial model. In August 2021, Zymergen disclosed that Hyaline had not achieved the anticipated customer adoption and that the market for foldable screens was smaller than expected. It also indicated that it did not expect meaningful revenue from the product in that year. Chief executive Joshua Hoffman resigned during the same period, and Jay Flatley became acting chief executive while continuing as chairman. The disclosures triggered a severe decline in the company’s share price, followed by investor litigation and a broad restructuring effort. Zymergen subsequently cut staff, renegotiated financing arrangements, and reduced or restructured office-related obligations. In November 2021 it abandoned Hyaline production and shifted its stated focus toward drug and vaccine development. The strategic change did not resolve the company’s financial position. In July 2022, Ginkgo Bioworks agreed to acquire Zymergen in an all-stock transaction valued at approximately $300 million. Zymergen later filed for Chapter 11 bankruptcy protection on October 3, 2023. In February 2024, it announced plans to liquidate after disposing of its remaining assets and laying off employees. The brand therefore represents a defunct synthetic-biology venture whose scientific platform and commercial ambitions did not mature into a sustainable standalone business.
History
Zymergen was established in 2013 by Joshua Hoffman, Zach Serber, and Jed Dean, who had met while working at Amyris. Their new company was built around the proposition that biological systems could be engineered as programmable production platforms. Rather than relying exclusively on traditional chemical synthesis, Zymergen sought to identify useful metabolic pathways, modify microorganisms, and use automated experimentation and machine-learning analysis to determine which strains and process conditions could produce target chemicals efficiently. The company’s intended market was broader than pharmaceutical biotechnology. It investigated chemicals and material building blocks for consumer products, industrial goods, electronics, and other manufacturing sectors. Its central commercial claim was that fermentation-based production could provide safer, less petroleum-dependent, and potentially less expensive alternatives to conventional processes. This proposition attracted considerable attention during the expansion of the synthetic-biology sector. Zymergen raised approximately $2 million in 2013 and approximately $44 million in 2015. In 2016 it received approximately $130 million from SoftBank’s Vision Fund. It raised a further approximately $400 million in 2018 and approximately $300 million in 2020. The company also reported relationships involving government research and large corporate customers. In 2018, it acquired Radiant Genomics, adding technology and personnel associated with genome mining and biological discovery. However, its fundraising success masked continuing challenges in converting research programs into dependable commercial manufacturing. Reports during this period indicated that the company was not generating revenue at the level expected by investors. Zymergen reduced its workforce by approximately 10% to 15% in 2020. It nevertheless continued to pursue a high-profile product strategy. In December 2020, it released Hyaline, a polyimide film manufactured using biologically produced diamine monomers. The film was transparent and flexible, and Zymergen promoted it for possible use in flexible smartphones, tablets, and related optical or electronic products. The company completed an initial public offering in April 2021, raising approximately $500 million. The offering placed Zymergen under greater public-market scrutiny. Securities filings disclosed that 2020 revenue was approximately $13 million while the company reported losses exceeding $262 million. The filings also described difficulties producing Hyaline and complaints from two companies that the material did not work with their manufacturing processes. These disclosures challenged the assumption that the company’s platform had already demonstrated scalable economics and caused a major fall in its market capitalization. Shareholder lawsuits followed. In August 2021, Zymergen acknowledged that Hyaline had not succeeded with customers and that demand for foldable-screen applications was smaller than forecast. The company also stated that it did not have an expected revenue source for that year. Hoffman resigned as chief executive and Jay Flatley became acting chief executive while serving as chairman. Zymergen then pursued cost reductions, including layoffs, loan renegotiation, and changes to office-lease commitments. Co-founder Jed Dean also departed. In November 2021, Zymergen abandoned Hyaline production and redirected its stated priorities toward drug and vaccine development. This was a significant reversal from the materials-centered commercial narrative that had supported its public listing. The company’s inability to bring its leading product to market, combined with its financing needs and market-value collapse, led commentators to compare its trajectory with other highly publicized biotechnology failures. In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for approximately $300 million in an all-stock deal. The transaction offered a possible route for preserving or integrating Zymergen’s technology and personnel, but Zymergen did not remain a viable independent public company. It filed for Chapter 11 bankruptcy on October 3, 2023. On February 5, 2024, it announced that it would liquidate after selling its remaining assets and laying off employees. Its corporate operations consequently ended, leaving Zymergen as a defunct example of the gap that can arise between synthetic-biology platform claims, pilot-scale production, customer qualification, and durable commercial revenue.
- 2024
Liquidation announced
[1]Zymergen announces liquidation after selling remaining assets and reducing its workforce.
- 2023
Chapter 11 filing
[1]Zymergen files for Chapter 11 bankruptcy protection on October 3.
- 2022
Agreement to be acquired by Ginkgo Bioworks
[1]Ginkgo Bioworks agrees to acquire Zymergen in an all-stock transaction valued at approximately $300 million.
- 2021
Initial public offering
[1]Zymergen completes an approximately $500 million IPO in April.
- 2021
Commercial setback and leadership change
[1]The company discloses Hyaline adoption and manufacturing problems; Joshua Hoffman resigns and Jay Flatley becomes acting chief executive.
- 2021
Hyaline production is abandoned
[1]Zymergen ends its Hyaline production effort and shifts its focus toward drugs and vaccines.
- 2020
Hyaline is introduced
[1]Zymergen announces Hyaline, a bio-manufactured polyimide film aimed at electronics and optical applications.
- 2018
Radiant Genomics acquisition
[1]Zymergen acquires Radiant Genomics to expand its biotechnology and genome-mining capabilities.
- 2016
SoftBank Vision Fund investment
[1]Zymergen receives approximately $130 million from SoftBank’s Vision Fund.
- 2015
Major private financing round
[1]The company raises approximately $44 million in private financing.
Products and positioning
An industrial biotechnology and synthetic-biology innovator seeking to replace or improve conventional chemical manufacturing through engineered microorganisms, automation, and machine learning.
Bio-manufactured polyimide film · 2020
Hyaline
Hyaline was Zymergen’s first publicly announced commercial product. It was a transparent, flexible polyimide film made from diamine monomers produced through biological manufacturing. Zymergen targeted electronics and optical applications, particularly flexible displays in smartphones and tablets. The product became the company’s main commercial test, but manufacturing difficulties and weak customer adoption prevented it from becoming a sustainable revenue stream. Zymergen abandoned production in November 2021.
Synthetic-biology platform output
Engineered microbial production strains
Zymergen designed and optimized genetically modified microorganisms intended to produce chemicals through fermentation. Its work combined genomic analysis, biological engineering, automated experimentation, and machine-learning models. These strains were developed as production tools or research outputs rather than as conventional consumer-facing products. The company’s stated applications included specialty chemicals, material inputs, consumer-goods ingredients, and pharmaceutical-related compounds.
Controversies
2021
Public-market disclosures about Hyaline and revenue performance
After its IPO, Zymergen disclosed limited revenue, very large losses, difficulties manufacturing Hyaline, and customer complaints concerning manufacturing compatibility. The disclosures contradicted optimistic commercial expectations, caused a major share-price decline, and were followed by shareholder lawsuits.
2021
Failure of the initial commercial product strategy
Zymergen acknowledged that Hyaline had not succeeded with customers and that the expected foldable-display market was smaller than projected. The company subsequently abandoned production and redirected its strategy.
Marketing campaigns
- 2020Hyaline commercial introduction
United States · Consumer electronics · Optical materials
Zymergen promoted Hyaline as a transparent and flexible bio-manufactured film for next-generation electronics, especially foldable screens and related optical applications.
Outcome. The product did not achieve the anticipated customer adoption and was later discontinued.
Brand decisions
2023
Chapter 11 bankruptcy filingOtherBackground
The company continued to face financial difficulties after its proposed acquisition and restructuring efforts.
Action taken
Zymergen filed for Chapter 11 bankruptcy protection on October 3, 2023.
Aftermath
The company later sold its remaining assets and announced liquidation.
2022
Agreement to sell Zymergen to Ginkgo BioworksM&ABackground
Zymergen’s commercial and financial difficulties left it seeking a strategic transaction after its independent public-company strategy deteriorated.
Action taken
Ginkgo Bioworks agreed to acquire Zymergen in an all-stock transaction reported at approximately $300 million.
Aftermath
Zymergen subsequently entered Chapter 11 bankruptcy and later announced liquidation.
Reported transaction value. Approximately $300 million (July 2022)
2021
Shift away from HyalineStrategyBackground
Hyaline faced manufacturing problems, customer adoption was weaker than expected, and the anticipated foldable-screen market did not develop at the forecast scale.
Action taken
Zymergen abandoned Hyaline production and stated that it would concentrate on drug and vaccine development.
Aftermath
The shift marked a retreat from the materials strategy that had been central to the company’s public-market narrative, while cost reductions and layoffs continued.
Recent events
Zymergen promotes Enakshi Singh to CFO[2]
Reported:
Zymergen announced that it had promoted Enakshi (Ena) Singh to chief financial officer.
- Unconfirmed
Zymergen acquires enEvolv[3]
Reported:
Zymergen reportedly acquired enEvolv, whose microbial screening and engineering technology could support Zymergen's biomanufacturing efforts. The enEvolv team was to join Zymergen as part of the transaction.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/zymergen · Editorial policy · How profiles are compiled